Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 18/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20853792 | 1.00 | QPCT (0.52) | QPCTESR1ESR2IP6K1QPCTL | |
| SCHEMBL29445215 | 1.00 | QPCT (0.52) | QPCTESR1ESR2IP6K1QPCTL | |
| SCHEMBL29445163 | 0.90 | QPCT (0.64) | QPCTQPCTL | |
| SCHEMBL20853753 | 0.90 | QPCT (0.64) | QPCTQPCTL | |
| SCHEMBL20853751 | 0.90 | QPCT (0.64) | QPCTQPCTL | |
| SCHEMBL20853782 | 0.90 | QPCT (0.64) | QPCTQPCTL | |
| SCHEMBL1444549 | 0.88 | QPCT (0.50) | QPCTIP6K1QPCTL | |
| SCHEMBL31513758 | 0.84 | ADRA1A (0.42) | QPCTQPCTL | |
| SCHEMBL1444543 | 0.84 | QPCT (0.72) | QPCTQPCTL | |
| SCHEMBL12274345 | 0.81 | QPCT (0.62) | QPCTIP6K1QPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | QPCT 1/4885ESR1 4403/4885ESR2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.